Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 37.9% on Friday . The stock traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares were traded during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 37.9 %
The business’s fifty day moving average price is C$0.09 and its two-hundred day moving average price is C$0.07. The firm has a market cap of C$17.42 million, a P/E ratio of -10.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What Investors Need to Know to Beat the Market
- Zymeworks in Focus for Insider Activity: Catalysts Ahead
- EV Stocks and How to Profit from Them
- Kura Sushi Stock Dips Into a Hot Buying Opportunity
- Investing in Commodities: What Are They? How to Invest in Them
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
